Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320317 | 0.82 | CYP3A4 (0.38) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL1319846 | 0.81 | TP53 (0.37) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL2273343 | 0.75 | CYP3A4 (0.45) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL1321183 | 0.75 | CYP3A4 (0.45) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL12808933 | 0.72 | CYP3A4 (0.42) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL12325473 | 0.72 | CYP3A4 (0.40) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL1320821 | 0.70 | LMNA (0.46) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL16576791 | 0.65 | CYP3A4 (0.45) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL28903680 | 0.63 | TP53 (0.66) | MAPTCYP3A4TP53SMN1; SMN2KDM4E | |
| SCHEMBL1319784 | 0.63 | PRKDC (0.55) | MAPTCYP3A4TP53SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035419-B1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-9051316-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051316-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8436180-B2 | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404709-B2 | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404723-B2 | 3-cyano 5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8404723-B2 | 3-cyano 5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8399471-B2 | Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399471-B2 | Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| WO-2008104306-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1926727-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008034534-A1 | 3-CYANO-5-THIAZAHETEROARYL-DIHYDROPYRIDINE AND THE USE THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140894-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | RYR1, TNNI3, RYR2 | MAPT 3226/4885CYP3A4 33/4885TP53 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.